Eyedeal Completes Enrollment for First Toric Intraocular Lens Clinical Trial in China

On April 18, Xi’an Eyedeal Medical Technology Co., Ltd. announced the successful completion of subject enrollment for the clinical trial of its first self-developed toric intraocular lens (IOL) designed for astigmatism correction in China.

This clinical trial is a multi-center, randomized, open-label, parallel-controlled study. A total of 188 participants were enrolled following rigorous screening. The trial is being conducted simultaneously at five renowned top-tier (Class A tertiary) hospitals and benchmarks against similar products from leading international companies, aiming to evaluate the safety and efficacy of the toric IOL.

The product is made using Eyedeal’s proprietary hydrophobic acrylic material platform. It is a foldable, single-piece, posterior chamber intraocular lens intended for visual correction in adult patients with aphakia and pre-existing corneal astigmatism following cataract extraction. The lens helps reduce residual astigmatism and decreases postoperative dependence on glasses.